<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e>, a mild ischemic condition, is associated with the <z:hpo ids='HP_0100543'>cognitive deficits</z:hpo> of AD </plain></SENT>
<SENT sid="1" pm="."><plain>Paeoniflorin (PF), a major constituent of peony root, was proved to be neuroprotective in middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we investigated whether PF could attenuate <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e>-induced learning dysfunction and brain damage in rat </plain></SENT>
<SENT sid="3" pm="."><plain>Seven weeks after permanent bilateral occlusion of the common carotid arteries, the rats were tested in the <z:mp ids='MP_0001465'>Morris water maze</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Subsequently, the animals were sacrificed and neurons, astrocytes and microglias were labeled with immunocytochemistry in hippocampus </plain></SENT>
<SENT sid="5" pm="."><plain>PF at the dose of 2.5 mg/kg ameliorated <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e>-related learning dysfunction and prevented CA1 neuron damage </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> increased the immunoreactivity of astrocytes and microglias in hippocampus </plain></SENT>
<SENT sid="7" pm="."><plain>The increase was prevented by PF at the dose of 2.5 mg/kg </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">Cerebral hypoperfusion</z:e> also increased expression of nuclear factor-kappaB (NF-kappaB), mostly in astrocytes, but not in neurons </plain></SENT>
<SENT sid="9" pm="."><plain>With the treatment of PF (2.5 mg/kg), NF-kappaB immunostaining was diminished in hippocampus </plain></SENT>
<SENT sid="10" pm="."><plain>Our results demonstrated that PF could attenuate <z:e sem="disease" ids="C0679466" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive deficit</z:e> and brain damage induced by <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> and that suppression of neuroinflammatory reaction in brain might be involved in PF-induced neuroprotection </plain></SENT>
</text></document>